30 Nov 05

Patients who could benefit from injectable therapies are a lot less needle-phobic than doctors assume, according to research conducted by pharmacist and behavioural scientist Professor Robert Horne. The “Open Mind” study presented at the 10th European AIDS Conference/EACS in Dublin showed over three quarters of patients would be willing to accept self-administered subcutaneous injectable therapy if offered.
Olwen Glynn Owen - PharmiWeb Field Reporter

30 Nov 05

As a major pharmaceutical market, Italy is a key region for the pharmaceutical industry. In terms of value, Italy’s pharmaceutical market is the fourth largest in Europe and represents around 13% of the regional total.
Dr Faiz Kermani

29 Nov 05

Japanese pharmaceutical companies have tended to avoid using mergers in their efforts to grow, but recent developments show that attitudes have changed.
Dr Faiz Kermani

28 Nov 05

The two peroxisome proliferator-activated receptor (PPAR) gamma agonists pioglitazone and rosiglitazone approved for treatment of type 2 diabetes achieved combined 2004 global sales of US$ 3.96 bln shared between Takeda & Eli Lilly (52 %) and GlaxoSmithKline (48 %).
La Merie Business Intelligence

25 Nov 05

In the first article on acquisitions and joint ventures, we saw how despite the odds on an acquisition adding value for shareholders being only one in three, companies like Johnson & Johnson, Pfizer, Sosei and Amphion Innovations are still racing ahead. Now we take a glimpse at the similarly challenging world of joint ventures – and then look at how companies can increase the odds with a little forward planning.
Peter Wolfe and Carolyn Douthwaite

23 Nov 05

Free Supplement on Mobile and Wireless Sales Force Strategies in Pharma - Find out how you can take advantage of the altest technologies, achieve implementation excellence and measure a ROI on sales force effeiciency!
eyeforpharma

17 Nov 05

e-Detailing is one of the pharmaceutical industry's biggest buzz terms of the moment, but it is one that, for the moment at least, seems unlikely to go away. This informative paper will help you under
Dr. Andree Bates

14 Nov 05

Acquisitions, joint ventures and strategic alliances have become the norm across industry and the life science and technology sectors are no exception.
Peter Wolfe and Carolyn Douthwaite

14 Nov 05

Ten years after the first approval of a recombinant human FSH for treatment of infertility the US$ 0.9 bln global market of recombinant human FSH (rhFSH) in 2004 was shared between Serono (63 % for follitropin alfa) and Organon (37 % for follitropin beta).
La Merie Business Intelligence

11 Nov 05

Due to demand, we at PharmiWeb have added a new Executive Jobs Listing to our comprehensive careers section. All these jobs include packages of over £100K (GBP) per year.
Mike Wood

31 Oct 05

For those new to the industry, a quick round up of the common abbreviations and what they stand for might be useful....
Elaine Ford

31 Oct 05

Patent expiry of recombinant tissue-type plasminogen activator (t-PA) and its TNK-derivative commencing in 2005 did not lead to biogeneric competition in regulated markets.
La Merie Business Intelligence

24 Oct 05

After Genentech had to terminate commercializtion of its Nutropin Depot preparation, the field now is lead by Korea-based LG Life Science and its European licensee BioPartners with the slow release formulation of hGH (LB03002)
La Merie Business Intelligence Press Release

22 Oct 05

Get your hands on this unique intelligence brought to you by eyeforpharma This supplement has authoritative case studies from the leading minds in pharmaceutical sales force effectiveness and will showcase sales force excellence and best practice. Click here (www.eyeforpharma.com/sales2006/pharmiweb1 ) to download your FREE copy!
eyeforpharma

17 Oct 05

More than 20 additional companies with activites in the biogeneric field of G-CSF were identified in a search conducted by La Merie Business Intelligence.
La Merie Business Intelligence PR

13 Oct 05

Biotechnology is seen as a key technology area for the future and like many other countries, South Africa is keen to develop its expertise in this field. The emphasis on biotechnology is certainly influenced to a large degree by the outstanding success of the US biotech industry – an economic feat that most other countries would like to emulate.
Britt Akermann and Dr Faiz Kermani

13 Oct 05

The prevalence of diabetes, in particular type 2 diabetes, is increasing worldwide. Type 2 diabetes increases with age, but recently has been affecting much younger individuals. In the UK, diabetes prevalence has doubled over the last 12-15 years, and is set to double again over a similar timeframe. The prevalence of diabetes in the UK is now, on average, 3.3%, though many patients are undiagnosed.
CSF Medical

10 Oct 05

The Business Intelligence firm La Merie S.L. recently analyzed the pipeline of thrombopoietin-stimulating agents. Main outcome of the search was that only two recombinant macromolecular proteins of the many projects initiated in the last decade are left.
Jorge Márquez

10 Oct 05

Bristol-Myers Squibb was named today as one of the 10 Best Companies for Working Mothers by Working Mother magazine. This is the eighth consecutive year that the company has been listed in the ranking of the 100 Best Companies, and the fifth year in a row Bristol-Myers Squibb has been named a Top 10 company.
Submitted Press Release

07 Oct 05

The European and US neuropathic pain markets are currently worth $2.5 billion combined. While most drugs currently used are not primarily indicated for neuropathic pain, the blockbuster status of Neurontin in this indication has focused the attention of several pharmaceutical giants on this potentially lucrative market. As such, Datamonitor expects the market to be worth over $4 billion by 2007.
Datamonitor

06 Oct 05

There is considerable pharmaceutical industry involvement in clinical research in Argentina. the country represents a major Latin American market and has one of the region's most advanced healthcare systems.
Dr Faiz Kermani

29 Sep 05

On Wednesday 22nd June, PharmiWeb Solutions and Microsoft brought together a senior group of sales and marketing professionals, to discuss how software and e-business based solutions can deliver competitive advantage for the pharmaceutical organisation.
Colin Williams

23 Sep 05

Pharma Sales World 2005 will provide delegates with a unique opportunity to gain critical business information about how Europe’s leading pharma companies are addressing the challenge of improving sales force effectiveness. The conference will highlight the issues of accessibility, emerging customer bases, market changes in the next decade, sales force size and structure, targeting and segmentation, the new breed of representative, data acquisition, training and development, customer relationshi
Hannah Reading

23 Sep 05

Fractures resulting from osteoporosis are widely recognised as a major cause of morbidity and mortality in the elderly population. It has been estimated that approximately 310,000 osteoporotic fractures occur annually in the UK, with a consequent cost to the health service of £1.7 billion.
CSF Medical

20 Sep 05

On Friday 16th September, before a glittering audience of local business Champions, Exco was awarded the highly acclaimed prize of Small Business of the Year 2005.
Sarah Eadon

26 Aug 05

Amrad and Merck & Co have selected a lead anti-IL-13 monoclonal antibody for development in severe asthma. The antibody holds promise for difficult-to-treat patients, and has sales potential in excess of $1 billion. Given asthma's complex pathophysiology, it is uncertain whether targeting this particular pathway will ultimately prove successful.
Datamonitor

22 Aug 05

It is often forgotten that until the late 1950s there was no treatment for schizophrenia, or for that matter, any other severe enduring mental illness. The majority of patients admitted to asylum care never left: hence the peak occupancy of 150,000 reported in the UK in 1955. As an interesting comparison, this is twice the current UK prison population.
CSF Medical

19 Aug 05

Merck KGaA has announced plans to consolidate its position in the highly competitive US generics market with the launch of new generics subsidiary, Genpharm LP. If the venture proves successful, it could catapult Merck KGaA into the global top three, behind Teva and Novartis. Datamonitor's Santwana Kar analyzes the reasons for and possible benefits of this move...
Datamonitor

18 Aug 05

According to LeadDiscovery's recent feature report, Pain Therapeutics 2005, about one and a half billion people suffer from moderate to severe chronic pain worldwide, driving the market for analgesics to nearly $23 billion in 2004. Many companies are investing heavily in the development of new pain therapeutics, even more so now with the recent problems to have hit the Cox-II inhibitors. Calcium channel blockers stepped into the spotlight at the end of last year with the FDA approval of Elan's Z
LeadDiscovery

18 Aug 05

Worth an estimated $35 billion in 2003, analysts predict that the sale of oncology therapeutics will grow to $60 billion by 2010. Targeted therapeutics represent one of the most exciting new developments in the field of oncology and include angiogenesis inhibitors; apoptosis stimulators and; signal transduction inhibitors. Apoptosis stimulators lead by Genta's Genesense are particularly appealing. Canadian researchers are focusing on a stimulator of apoptosis known as pancratistatin. This molecu
LeadDiscovery